1 / 1

Technology Available for Licensing

US Army Medical Research and Materiel Command. Technology Available for Licensing. Real-time PCR Assay for a Unique Chromosomal Sequence of Bacillus anthracis.

rory
Download Presentation

Technology Available for Licensing

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. US Army Medical Research and Materiel Command Technology Available for Licensing Real-time PCR Assay for a Unique Chromosomal Sequence of Bacillus anthracis This invention is a method to provide a real-time polymerase chain reaction (PCR) assay for the detection of chomosomal DNA from Bacillus anthracis, the spore-forming, gram-positive bacterium that causes anthrax. Although the presence of B. anthracis can be identified clinically using Gram stain, colony morphology, and various biochemical tests, the methods are time-consuming. Real-time PCR assays are preferred because they are faster, less labor intensive, and add the specificity of a probe. The Bacillus species are genetically indistinguishable from each other. Two chromosomal targets, the rpoB and gyrA genes, have been published. However, they are not unique to B. anthracis and have resulted in false positives. Previous real-time PCR assays identified B. anthracis based on the presence of the toxin-coding plasmid (pX01) and capsule-encoding plasmid (pX02) that give B. anthracis its virulence. The invention provides a means to identify B. anthracis strains that lack pX01 or pX02. The unique chromosomal sequence of the invention relied on a genomic hybridization study that used nucleic acid isolated from B. cereus ATCC 21769 and genomic DNA from the plasmid-cured B. anthracis strain Delta ANR-SWS. The invention could verify the presence of B. anthracis independent of plasmid occurrence. It provides a reliable chromosomal assay that was previously lacking. • Features and advantages: • • Demonstrated 100% sensitivity to 45 studied B. anthracis strains • • Demonstrated 100% specificity against 62 tested Bacillus species • • Assay is significantly aligned with the B. anthracis AMES strain • Assay is homologous to an abhydrolase from B. anthracis strain A2012 Patent Status Publication No.:20050214787Date Published:September 29, 2005 Available from:www.uspto.govDocket No.:RIID 04-12 Point of Contact Dr. Paul C. Mele Director, Office of Research and Technology Applications USAMRMC, MCMR-ZA-J 504 Scott St., Ft. Detrick, MD 21702-5012 E-mail: usamrmcorta@det.amedd.army.mil Voice: 301-619-6664/2065/7219 Fax: 301-619-5034 KEYWORDS: Bacillus anthracis; anthrax; chromosome; Taq-man; real-time PCR Licensing Opportunities • Patent licenses are available to companies with commercial interests

More Related